Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2

被引：2
作者：
Cui, HM
Onyango, P
Brandenburg, S
Wu, YQ
Hsieh, CL
Feinberg, AP
机构：
[1] Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA
[5] Univ So Calif, Sch Med, Dept Urol, Los Angeles, CA 90033 USA
[6] Univ So Calif, Sch Med, Dept Biochem, Los Angeles, CA 90033 USA
[7] Univ So Calif, Sch Med, Dept Mol Biol, Los Angeles, CA 90033 USA
来源：
CANCER RESEARCH | 2002年 / 62卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Epigenetic alterations in human cancers include global DNA hypomethylation, gene hypomethylation and promoter hypermethylation, and loss of imprinting (LOI) of the insulin-like growth factor-II gene (IGF2). A mechanism for LOI described previously is hypermethylation of a differentially methylated region (DMR) upstream of the H19 gene, allowing activation of the normally silent maternal allele of IGF2. Here we show that this mechanism does not apply to colorectal cancers, which show hypomethylation of the H19 DMR as well as a DMR upstream of exon 3 of IGF2. This hypomethylation is found in both colorectal cancers and normal mucosa from the same patients, and in cell lines with somatic cell knockout of DNA methyltransferases DNMT1 and DNMT3B. These data suggest that hypomethylation is a mechanism for LOI, that the popular IGF2-H19 enhancer competition model for IGF2 imprinting does not apply to the human colon, and that an alternative model for LOI would involve a transcriptional repressor acting on the normally silent maternal allele of IGF2.
引用
收藏
页码：6442 / 6446
页数：5
相关论文
共 40 条
[21]   5' CPG ISLAND METHYLATION IS ASSOCIATED WITH TRANSCRIPTIONAL SILENCING OF THE TUMOR-SUPPRESSOR P16/CDKN2/MTS1 IN HUMAN CANCERS [J].
MERLO, A ;
HERMAN, JG ;
MAO, L ;
LEE, DJ ;
GABRIELSON, E ;
BURGER, PC ;
BAYLIN, SB ;
SIDRANSKY, D .
NATURE MEDICINE, 1995, 1 (07) :686-692
[22]   EPIGENETIC LESIONS AT THE H19 LOCUS IN WILMS-TUMOR PATIENTS [J].
MOULTON, T ;
CRENSHAW, T ;
HAO, Y ;
MOOSIKASUWAN, J ;
LIN, N ;
DEMBITZER, F ;
HENSLE, T ;
WEISS, L ;
MCMORROW, L ;
LOEW, T ;
KRAUS, W ;
GERALD, W ;
TYCKO, B .
NATURE GENETICS, 1994, 7 (03) :440-447
[23]   Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer [J].
Nakagawa, H ;
Chadwick, RB ;
Peltomäki, P ;
Plass, C ;
Nakamura, Y ;
de la Chapelle, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (02) :591-596
[24]   RELAXATION OF INSULIN-LIKE GROWTH FACTOR-II GENE IMPRINTING IMPLICATED IN WILMS-TUMOR [J].
OGAWA, O ;
ECCLES, MR ;
SZETO, J ;
MCNOE, LA ;
YUN, K ;
MAW, MA ;
SMITH, PJ ;
REEVE, AE .
NATURE, 1993, 362 (6422) :749-751
[25]   CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease [J].
Ohlsson, R ;
Renkawitz, R ;
Lobanenkov, V .
TRENDS IN GENETICS, 2001, 17 (09) :520-527
[26]   DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development [J].
Okano, M ;
Bell, DW ;
Haber, DA ;
Li, E .
CELL, 1999, 99 (03) :247-257
[27]  
Pedersen IS, 1999, CANCER RES, V59, P5449
[28]   RELAXATION OF IMPRINTED GENES IN HUMAN CANCER [J].
RAINIER, S ;
JOHNSON, LA ;
DOBRY, CJ ;
PING, AJ ;
GRUNDY, PE ;
FEINBERG, AP .
NATURE, 1993, 362 (6422) :747-749
[29]  
RAINIER S, 1995, CANCER RES, V55, P1836
[30]   Loss of imprinting in disease progression in chronic myelogenous leukemia [J].
Randhawa, GS ;
Cui, HM ;
Barletta, JA ;
Strichman-Almashanu, LZ ;
Talpaz, M ;
Kantarjian, H ;
Deisseroth, AB ;
Champlin, RC ;
Feinberg, AP .
BLOOD, 1998, 91 (09) :3144-3147
1234